Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

DexCom Inc. Stock , DXCM

113.93 0.00 0.00%
Official Close 3/17/2023 NAS
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 03/17/2023 the closing price of the DexCom Inc. share was $113.93 on NAS. Compared to the opening price on Friday 03/17/2023 on NAS of $114.56, this is a drop of 0.55%. DexCom Inc.'s market capitalization is $43.96 B by 386.41 M shares outstanding.
Is DexCom stock a Buy, Sell or Hold? DexCom stock has received a consensus rating of buy. The average rating score is and is based on 35 buy ratings, 15 hold ratings, and 0 sell ratings.
What was the 52-week low for DexCom stock? The low in the last 52 weeks of DexCom stock was 66.94. According to the current price, DexCom is 170.20% away from the 52-week low.
What was the 52-week high for DexCom stock? The high in the last 52 weeks of DexCom stock was 134.50. According to the current price, DexCom is 84.71% away from the 52-week high.
What are analysts forecasts for DexCom stock? The 50 analysts offering price forecasts for DexCom have a median target of 361.04, with a high estimate of 750.00 and a low estimate of 83.00. The median estimate represents a 31.56 difference from the last price of 113.93.

DexCom Stock Snapshot

113.89
Bid
4,000.00
Bid Size
113.93
Ask
1,400.00
Ask Size
3/17/2023
Date
8:00 PM
Time
1.41 M
Volume
114.56
Prev. Close
114.56
Open
43.96 B
Market Cap
386.41 M
Number of Shares
113.06
Day Low
115.44
Day High
113.93
66.94
52 Week Low
134.50
52 Week High
113.93
128.43
P/E Ratio
98.44
Free Float in %
1.05
EPS 2023
6.89
Book Value per Share
2.27
Cash Flow per Share

DexCom Historical Prices

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

DexCom Analyst Data

Total Analysts: 50
Buy Ratings: 35 Neutral Ratings: 15 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 83.00 Median: 361.04 Highest: 750.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

DexCom Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
02/13/23 Barclays Capital
Maintained Hold $110
02/10/23 Cowen and Company, LLC
Maintained Buy $125
01/26/23 Wolfe Research
Maintained Buy $121
01/06/23 Morgan Stanley
Maintained Hold $131
12/12/22 Citigroup Corp.
Maintained Buy $146
10/28/22 Morgan Stanley
Maintained Hold $117
10/28/22 Wells Fargo & Co
Maintained Buy $128
10/28/22 Raymond James Financial, Inc.
Maintained Buy $125
10/18/22 Barclays Capital
Maintained Hold $103
10/12/22 Jefferies & Company Inc.
Maintained Buy $125
10/11/22 Morgan Stanley
Maintained Hold $107
10/10/22 BTIG Research
Maintained Buy $110
10/07/22 Stifel, Nicolaus & Co., Inc.
Maintained Buy $120
10/07/22 Piper Sandler
Maintained Buy $120
08/01/22 Raymond James Financial, Inc.
Maintained Buy $101
07/29/22 Morgan Stanley
Maintained Hold $83
07/29/22 Piper Sandler
Maintained Buy $110
07/15/22 Bernstein
Maintained Buy $105
06/24/22 BTIG Research
Maintained Buy $105
06/13/22 Morgan Stanley
Maintained Hold $90.75
06/07/22 Morgan Stanley
Maintained Hold $363
05/17/22 Citigroup Corp.
Maintained Buy $525
04/29/22 Raymond James Financial, Inc.
Maintained Buy $486
04/29/22 Morgan Stanley
Maintained Hold $492
04/29/22 Piper Sandler
Maintained Buy $480
04/29/22 SVB Leerink
Maintained Buy $500
02/11/22 Morgan Stanley
Maintained Hold $514
02/03/22 BTIG Research
Upgraded to Buy $535
01/19/22 Wells Fargo & Co
Upgraded to Buy $575
01/19/22 Raymond James Financial, Inc.
Maintained Buy $538
01/07/22 Morgan Stanley
Maintained Hold $570
01/07/22 Guggenheim
Upgraded to Buy $580
11/03/21 Piper Sandler
Maintained Buy $750
11/01/21 Raymond James Financial, Inc.
Maintained Buy $618
10/29/21 Morgan Stanley
Maintained Hold $576
10/29/21 SVB Leerink
Maintained Buy $715
10/18/21 Guggenheim
Downgraded to Hold
09/16/21 Piper Sandler
Maintained Buy $650
08/02/21 Morgan Stanley
Maintained Hold $510
07/30/21 Piper Sandler
Maintained Buy $550
07/30/21 Capital Depesche
Maintained Buy $500
07/30/21 Oppenheimer & Co. Inc.
Maintained Buy $525
07/30/21 Raymond James Financial, Inc.
Maintained Buy $515
07/30/21 Wells Fargo & Co
Maintained Hold $475
07/30/21 SVB Leerink
Maintained Buy $500
05/28/21 Wells Fargo & Co
Upgraded to Hold $380
05/25/21 Barclays Capital
Maintained Buy $500
04/30/21 Capital Depesche
Maintained Buy $455
04/30/21 Raymond James Financial, Inc.
Maintained Buy $466
04/30/21 Citigroup Corp.
Maintained Buy $488

DexCom Estimates* in USD

  2023 2024 2025 2026 2027
Revenue 3,466 4,163 4,895 5,786 6,330
Dividend - 0.00 0.00 - -
Dividend Yield (in %) - - - - -
EPS 1.05 1.45 1.82 2.25 2.46
P/E Ratio 109.24 79.10 63.01 51.09 46.73
EBIT 571 793 1,009 1,334 1,393
EBITDA 820 1,067 1,315 - -
Net Profit 428 608 788 1,050 1,095
Net Profit Adjusted 428 608 788 1,050 1,095
Pre-Tax Profit 564 790 1,011 1,371 1,386
Net Profit (Adjusted) 565 776 953 - -
EPS (Non-GAAP) ex. SOE 1.05 1.45 1.82 2.25 2.46
EPS (GAAP) 1.04 1.44 1.82 2.67 -
Gross Income 2,181 2,672 3,163 3,791 4,178
Cash Flow from Investing -176 -86 -58 - -
Cash Flow from Operations 873 978 1,184 - -
Cash Flow from Financing -166 -334 - - -
Cash Flow per Share 2.27 2.44 2.95 - -
Free Cash Flow 474 595 746 - -
Free Cash Flow per Share 1.07 1.46 1.87 - -
Book Value per Share 6.89 7.67 6.07 - -
Net Debt 117 -320 -390 - -
Research & Development Exp. 531 620 727 835 1,013
Capital Expenditure 323 329 319 - -
Selling, General & Admin. Exp. 1,072 1,267 1,438 1,623 1,772
Shareholder’s Equity 2,716 3,222 3,476 - -
Total Assets 5,737 6,339 6,564 - -
  Previous Quarter
ending 12/31/22 		Current Quarter
ending 03/31/23 		Next Quarter
ending 06/30/23 		Current Year
ending 12/31/23 		Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts 18 17 17 19 18
Average Estimate 0.273 USD 0.145 USD 0.220 USD 1.052 USD 1.453 USD
Year Ago 0.170 USD 0.080 USD 0.170 USD 0.870 USD 1.052 USD
Publish Date 2/9/2023 5/3/2023 8/2/2023 - -
Revenue Estimates
No. of Analysts 17 15 15 19 18
Average Estimate 810 USD 721 USD 831 USD 3,466 USD 4,163 USD
Year Ago 698 USD 629 USD 696 USD 2,910 USD 3,466 USD
Publish Date 2/9/2023 5/3/2023 8/2/2023 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

DexCom Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Dolan Matthew Vincent 03/15/2023 2,303.00 33,569.00 115.00 Sell No
Stern Sadie 03/13/2023 393.00 83,645.00 111.86 Sell No
Dolan Matthew Vincent 03/12/2023 6,229.00 35,872.00 106.27 Sell No
Flynn Paul R 03/12/2023 2,782.00 54,893.00 106.27 Sell No
Regan Barry J. 03/12/2023 2,010.00 70,472.00 106.27 Sell No
Stern Sadie 03/09/2023 3,565.00 84,038.00 111.40 Sell No
Stern Sadie 03/09/2023 2,550.00 87,603.00 111.40 Sell No
Dolan Matthew Vincent 03/09/2023 787.00 42,101.00 111.40 Sell No
Dolan Matthew Vincent 03/09/2023 2,397.00 42,888.00 111.40 Sell No
Dolan Matthew Vincent 03/09/2023 1,650.00 45,285.00 111.40 Sell No
Dolan Matthew Vincent 03/09/2023 1,370.00 46,935.00 111.40 Sell No
Selvaraj Shelly Ramasamy 03/09/2023 2,646.00 54,512.00 111.40 Sell No
Selvaraj Shelly Ramasamy 03/09/2023 1,737.00 57,158.00 111.40 Sell No
Selvaraj Shelly Ramasamy 03/09/2023 2,089.00 58,895.00 111.40 Sell No
Balo Andrew K 03/09/2023 3,275.00 59,303.00 111.40 Sell No
Balo Andrew K 03/09/2023 5,990.00 50,908.00 111.40 Sell No
Balo Andrew K 03/09/2023 2,405.00 56,898.00 111.40 Sell No
Leach Jacob Steven 03/09/2023 4,583.00 290,377.00 111.40 Sell No
Leach Jacob Steven 03/09/2023 7,986.00 294,960.00 111.40 Sell No
Leach Jacob Steven 03/09/2023 3,540.00 302,946.00 111.40 Sell No
Abbey Donald 03/09/2023 3,390.00 208,023.00 111.40 Sell No
Abbey Donald 03/09/2023 4,675.00 211,413.00 111.40 Sell No
Abbey Donald 03/09/2023 3,604.00 216,088.00 111.40 Sell No
SAYER KEVIN R 03/09/2023 11,047.00 348,269.00 111.40 Sell No
SAYER KEVIN R 03/09/2023 9,141.00 359,316.00 111.40 Sell No

DexCom Dividend Calendar

Date Name Dividend *yield Currency
2022 DexCom Inc. - - USD
2021 DexCom Inc. - - USD
2020 DexCom Inc. - - USD
2019 DexCom Inc. - - USD
2018 DexCom Inc. - - USD
2017 DexCom Inc. - - USD
2016 DexCom Inc. - - USD
2015 DexCom Inc. - - USD
2014 DexCom Inc. - - USD
2013 DexCom Inc. - - USD
2012 DexCom Inc. - - USD
2011 DexCom Inc. - - USD
2010 DexCom Inc. - - USD
2009 DexCom Inc. - - USD
*Yield of the Respective Date

DexCom Inc. Calendar

Event Estimate Info Date
Earnings Report 0.145 USD Q1 2023 Earnings Release 05/03/2023
Earnings Report 0.220 USD Q2 2023 Earnings Release 08/02/2023
Earnings Report - Q3 2023 Earnings Release 11/08/2023
Earnings Report - Q4 2023 Earnings Release 02/08/2024

DexCom Inc. Past Events

Event Actual EPS Info Date
Earnings Report 0.340 USD Q4 2022 Earnings Release 02/09/2023
Press Conference - - 10/27/2022
Shareholders' Meeting - - 05/19/2022

DexCom Profile

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
4
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

DexCom Shareholder

Owner in %
Freefloat 98.44
Vanguard Group, Inc. (Subfiler) 10.92
Baillie Gifford & Co. 4.87
Baillie Gifford & Co. 4.48
State Street Corp. 4.26
Sands Capital Management LLC 4.01
BlackRock Fund Advisors 3.46
Vanguard Total Stock Market Index Fund 3.08
Capital Research & Management Co. (Global Investors) 2.45
Jennison Associates LLC 2.38
Vanguard Mid Cap Index Fund 2.33
Vanguard 500 Index Fund 2.32
BlackRock Institutional Trust Co. NA 2.15
Geode Capital Management LLC 2.10
JPMorgan Investment Management, Inc. 1.98
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

DexCom Management

Name Job
Nicholas Augustinos Board of Director
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Teri Lawver Chief Commercial Officer
Jereme M Sylvain Chief Financial Officer & EVP-Finance
Sadie M Stern Chief Human Resources Officer & Executive VP
Shelly R. Selvaraj Chief Information Officer & Senior Vice President
Michael J. Brown Chief Legal Officer & Executive Vice President
Jacob S. Leach Chief Operating Officer & Executive Vice President
Girish Naganathan Chief Technology Officer & EVP
Sean Christensen Director-Corporate Affairs & Head-IR
Andrew K. Balo EVP-Global Medical Affairs, Access & Evidence
Donald M. Abbey Executive VP-Quality & Regulatory Affairs
Barry J. Regan Executive Vice President-Global Operations
Paul R. Flynn Executive Vice President-Global Revenue
Steven R. Altman Independent Director
Jay S. Skyler Independent Director
Eric J. Topol Independent Director
Karen M. Dahut Independent Director
Bridgette P. Heller Independent Director
Richard Alexander Collins Independent Director
Kyle J. Malady Independent Director
Barbara E. Kahn Independent Director
Mark G. Foletta Lead Independent Director
Matt V. Dolan SVP-Strategy, Corporate Development & New Markets